MX2020010071A - Polipeptidos anti-microbianos, derivados de bacteriofago, y sus usos contra bacterias gram negativas. - Google Patents
Polipeptidos anti-microbianos, derivados de bacteriofago, y sus usos contra bacterias gram negativas.Info
- Publication number
- MX2020010071A MX2020010071A MX2020010071A MX2020010071A MX2020010071A MX 2020010071 A MX2020010071 A MX 2020010071A MX 2020010071 A MX2020010071 A MX 2020010071A MX 2020010071 A MX2020010071 A MX 2020010071A MX 2020010071 A MX2020010071 A MX 2020010071A
- Authority
- MX
- Mexico
- Prior art keywords
- negative bacteria
- chp
- disclosed
- gram
- bacteriophage
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- 241000894006 Bacteria Species 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 230000000845 anti-microbial effect Effects 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 241001515965 unidentified phage Species 0.000 title 1
- 241000894007 species Species 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14211—Microviridae
- C12N2795/14222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14211—Microviridae
- C12N2795/14231—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14211—Microviridae
- C12N2795/14233—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
En el presente documento se describen composiciones farmacéuticas que comprenden una cantidad efectiva de un péptido Chp aislado que tiene una secuencia de aminoácidos seleccionada del grupo que consiste en las SEQ ID NOs. 1-4, 6-26 y 54-66, o un péptido Chp modificado que tiene aproximadamente 80% de identidad de secuencia con el mismo, en el que el péptido Chp modificado inhibe el crecimiento, reduce la población o mata al menos una especie de bacterias Gram-negativas; y un vehículo farmacéuticamente aceptable. También se describen en el presente documento péptidos Chp aislados, así como vectores que comprenden una molécula de ácido nucleico que codifica los péptidos Chp y las células huésped que comprenden un vector. También se describen en el presente documento métodos para inhibir el crecimiento, reducir la población, o matar al menos una especie de bacterias Gram-negativas y métodos para tratar una infección bacteriana en un sujeto.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862650235P | 2018-03-29 | 2018-03-29 | |
PCT/US2019/024854 WO2019191598A1 (en) | 2018-03-29 | 2019-03-29 | Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020010071A true MX2020010071A (es) | 2021-01-08 |
Family
ID=68058481
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020010071A MX2020010071A (es) | 2018-03-29 | 2019-03-29 | Polipeptidos anti-microbianos, derivados de bacteriofago, y sus usos contra bacterias gram negativas. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210330738A1 (es) |
EP (1) | EP3773669A4 (es) |
JP (1) | JP2021519311A (es) |
KR (1) | KR20210005027A (es) |
CN (1) | CN112368010A (es) |
AU (1) | AU2019245333A1 (es) |
BR (1) | BR112020019010A2 (es) |
CA (1) | CA3096236A1 (es) |
IL (1) | IL277399A (es) |
MX (1) | MX2020010071A (es) |
WO (1) | WO2019191598A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021519083A (ja) | 2018-03-29 | 2021-08-10 | コントラフェクト コーポレイション | 溶解素−抗微生物ペプチド(amp)ポリペプチドコンストラクト、溶解素、それをコードする単離ポリヌクレオチド及びその使用 |
JP2022539383A (ja) * | 2019-07-05 | 2022-09-08 | コントラフェクト コーポレイション | 抗微生物性のバクテリオファージ由来のポリペプチド、並びにグラム陰性細菌及び抗酸菌に対するそれらの使用 |
EP4058468A4 (en) * | 2019-11-14 | 2024-04-10 | Contrafect Corp | POLYPEPTIDE CONSTRUCTIONS OF ANTIMICROBIAL PEPTIDE LYSINE (AMP), LYSINES, ISOLATED POLYNUCLEOTIDES ENCODING THEREFOR AND USES THEREOF |
WO2021211303A1 (en) * | 2020-04-14 | 2021-10-21 | Contrafect Corporation | Antiviral, bacteriophage-derived polypeptides and their use against viruses |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2447823A1 (en) * | 2001-05-23 | 2002-11-28 | The University Of British Columbia | Diagnosis of vascular disease susceptibility using bacteriophage phi-cpn1 host chlamydia |
WO2004104174A2 (en) * | 2003-05-16 | 2004-12-02 | North Carolina State University | Polyubiquitin rubi3 promoter and 5' regulatory sequences |
EP3248985B1 (en) * | 2007-01-19 | 2019-10-23 | Kai Pharmaceuticals, Inc. | Modifications of peptide compositions to increase stability and delivery efficiency |
WO2010141135A2 (en) * | 2009-03-05 | 2010-12-09 | Trustees Of Boston University | Bacteriophages expressing antimicrobial peptides and uses thereof |
EP2839010B1 (en) * | 2012-03-19 | 2018-04-25 | Madeleine Pharmaceuticals Pty Ltd | Method of producing a recombinant peptide |
AU2016324307B2 (en) * | 2015-09-17 | 2021-10-21 | Contrafect Corporation | Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby |
JP2021519083A (ja) * | 2018-03-29 | 2021-08-10 | コントラフェクト コーポレイション | 溶解素−抗微生物ペプチド(amp)ポリペプチドコンストラクト、溶解素、それをコードする単離ポリヌクレオチド及びその使用 |
CN112292143A (zh) * | 2018-08-23 | 2021-01-29 | 康特拉费克特公司 | 溶素-抗微生物肽(amp)多肽构建体、溶素、其分离的编码多核苷酸及其用途 |
JP2022539383A (ja) * | 2019-07-05 | 2022-09-08 | コントラフェクト コーポレイション | 抗微生物性のバクテリオファージ由来のポリペプチド、並びにグラム陰性細菌及び抗酸菌に対するそれらの使用 |
EP4058468A4 (en) * | 2019-11-14 | 2024-04-10 | Contrafect Corp | POLYPEPTIDE CONSTRUCTIONS OF ANTIMICROBIAL PEPTIDE LYSINE (AMP), LYSINES, ISOLATED POLYNUCLEOTIDES ENCODING THEREFOR AND USES THEREOF |
US20210324359A1 (en) * | 2020-04-17 | 2021-10-21 | Contrafect Corporation | Use of gram-negative lysin-antimicrobial peptide (amp) polypeptide constructs in treating endocarditis |
-
2019
- 2019-03-29 AU AU2019245333A patent/AU2019245333A1/en active Pending
- 2019-03-29 JP JP2020551971A patent/JP2021519311A/ja active Pending
- 2019-03-29 EP EP19774811.4A patent/EP3773669A4/en active Pending
- 2019-03-29 MX MX2020010071A patent/MX2020010071A/es unknown
- 2019-03-29 CN CN201980036013.5A patent/CN112368010A/zh active Pending
- 2019-03-29 CA CA3096236A patent/CA3096236A1/en active Pending
- 2019-03-29 US US17/041,638 patent/US20210330738A1/en active Pending
- 2019-03-29 WO PCT/US2019/024854 patent/WO2019191598A1/en active Application Filing
- 2019-03-29 BR BR112020019010-1A patent/BR112020019010A2/pt unknown
- 2019-03-29 KR KR1020207030981A patent/KR20210005027A/ko active Search and Examination
-
2020
- 2020-09-16 IL IL277399A patent/IL277399A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3773669A4 (en) | 2022-04-27 |
EP3773669A1 (en) | 2021-02-17 |
US20210330738A1 (en) | 2021-10-28 |
AU2019245333A1 (en) | 2020-10-29 |
RU2020131450A (ru) | 2022-04-29 |
CN112368010A (zh) | 2021-02-12 |
IL277399A (en) | 2020-11-30 |
KR20210005027A (ko) | 2021-01-13 |
WO2019191598A1 (en) | 2019-10-03 |
CA3096236A1 (en) | 2019-10-03 |
BR112020019010A2 (pt) | 2020-12-29 |
JP2021519311A (ja) | 2021-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020010071A (es) | Polipeptidos anti-microbianos, derivados de bacteriofago, y sus usos contra bacterias gram negativas. | |
Sinha et al. | Antimicrobial lactoferrin peptides: the hidden players in the protective function of a multifunctional protein | |
Yoo et al. | Bovine lactoferrin and lactoferricin TM inhibit tumor metastasis in mice | |
US10017542B2 (en) | Antimicrobial peptides and methods of use thereof | |
MX2020008860A (es) | Lisinas plyss2 modificadas y sus usos. | |
NZ602351A (en) | Axmi-115, axmi-113, axmi-005, axmi-163 and axmi-184 : vip3a insecticidal proteins from bacillus thuringiensis and methods for their use | |
KR101896927B1 (ko) | 흰점박이꽃무지에서 유래한 항균 펩타이드 프로테티아마이신 1 및 그의 조성물 | |
MX2021015563A (es) | Polipéptidos anti-microbianos, derivados de bacteriófago, y sus usos contra bacterias gramnegativas y acidorresistentes. | |
BR9205760A (pt) | Proteínas antimicrobiais, proteína pura MJ-AMPI, proteínas puras, sequência de DNA recombinante, vetor, sistema biológico, plantas, composição antimicrobial, processo para combater fungos ou bactérias e processo de extração para produzir proteínas biocidamente ativas | |
Harris et al. | Anionic antimicrobial peptides from eukaryotic organisms and their mechanisms of action | |
CN102781953A (zh) | 寡肽化合物及其应用 | |
WO2018155813A3 (ko) | 엔테로코쿠스 패슘에 대하여 용균력을 가지는 신규한 항균단백질 efal-2 | |
EP3268023A2 (en) | Combination of bactericidal agent with a lysosomotropic alkalinising agent for the treatment of a bacterial infection | |
KR101889396B1 (ko) | 흰점박이꽃무지에서 유래한 항균 펩타이드 프로테티아마이신 2 및 그의 조성물 | |
ES2382466T3 (es) | Péptidos inductores de bacteriocinas | |
KR20170053879A (ko) | 벼메뚜기에서 유래한 항균 펩타이드 옥시야신-1 및 그의 조성물 | |
KR20170053877A (ko) | 벼메뚜기에서 유래한 항균 펩타이드 옥시야신-2 및 그의 조성물 | |
KR101444256B1 (ko) | 왕지네로부터 분리한 신규 스콜로펜드라신ⅲ 펩타이드 및 그의 조성물 | |
JP2017522280A (ja) | 特に獣医学分野用の消毒剤および抗微生物組成物 | |
JP2019523220A5 (es) | ||
BR9307429A (pt) | Proteìna antimicrobiana, composição, sequência de dna recombinante, promotor de sequência, vetor, sistema biológico, planta, sementes e progenitura, processo de combate a fungos ou bactérias e processo de extração para a produção de uma proteìna | |
ATE551353T1 (de) | Protein mit fusogener wirkung, nukleinsäuresequenzen, die für dieses protein codieren und pharmazeutische zusammensetzungen, die dieses enthalten | |
JP2005120050A (ja) | 新規抗菌性ペプチドとその利用 | |
ATE411812T1 (de) | Peptide zur behandlung von infektionen mit dem herpes-virus | |
WO2001012668A9 (en) | Cathelicidin-derived peptides with broad spectrum antimicrobial activity |